Posting of Annual Report & Notice of AGM

RNS Number : 3753Z

ValiRx PLC

26 May 2016

 

ValiRx Plc

("ValiRx" or the "Company")

Posting of Annual Report and Accounts

&

Notice of Annual General Meeting

London, UK, 26 May 2016: ValiRx Plc (AIM: VAL) is a life science company with a focus on cancer therapeutics and diagnostics for personalised medicine.

The Company announces that its Annual Report and Accounts for the year ended 31 December 2015 has been published, are available on the Company's website, www.valirx.com and will be posted to registered shareholders shortly.

The Company also advises that the Notice of its Annual General Meeting ("AGM"), its Chairman's Letter to Shareholders and the Form of Proxy for the AGM are now available on its website, www.valirx.com and these will also be posted to registered shareholders.

The Company's AGM will be held on 20 June 2016 at 10.00am at the offices of Nabarro LLP at 125 London Wall, London, EC2Y 5AL.

*** ENDS ***

For more information, please contact:

ValiRx plc	Tel: [phone] www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: [phone]
Tarquin Edwards, Head of Communications.	Tel: [phone] [e-mail]
Mark Treharne, Corporate Development Manager	Tel: [phone] [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel: [phone]
Liam Murray / Avi Robinson
Northland Capital Partners Limited (Broker)	Tel: [phone]
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking)

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company has undertaken to develop a novel and groundbreaking class of therapeutics across a number of fields in oncology and has taken its lead compound, Val201, into Phase I/II clinical trials.   The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006.

The Company has a pipeline of other therapeutic drugs, which are currently progressing towards clinical trials. The product focus is in the targeted analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

It actively manages projects within its portfolio as a trading company.  The ValiRx business model spreads the risks of life science technology development by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

1. ValiPharma is the therapeutics division, with two embedded technologies primarily directed at the treatment of cancers.

2. ValiFinn is the biomarkers and diagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology later in the year to strengthen the portfolio.

3. ValiSeek is a joint venture between ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentially other indications.

 

END

 

 

MSCAFMFTMBATMRF